Literature DB >> 29848260

Optimization of Protein and Peptide Drugs Based on the Mechanisms of Kidney Clearance.

Huizi Wu1,2, Jiaguo Huang3.   

Abstract

BACKGROUND: Development of proteins and peptides into drugs has been considered as a promising strategy to target certain diseases. However, only few proteins and peptides have been approved as new drugs into the market each year. One major problem is that proteins and peptides often exhibit short plasma half-life times, which limits the application for their clinical use. In most cases a short half-life time is not effective to deliver sufficient amount of drugs to the target organs and tissues, which is generally caused by fast renal clearance and low plasma stability due to proteolytic degradation during systemic circulation, because that the most common clearance pathway of small proteins and peptides is through glomerular filtration by the kidneys.
CONCLUSION: In this review, enzymatic degradation of proteins and peptides were discussed. Furthermore, several approaches to lengthen the half-life of peptides and proteins drugs based on the unique structures of glomerular capillary wall and the mechanisms of glomerular filtration were summarized, such as increasing the size and hydrodynamic diameter; increasing the negative charge to delay the filtration; increasing plasma protein binding to decrease plasma clearance. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Keywords:  Kidney clearance; enzymatic degradation; glomerular filtration; peptides drugs; plasma half-life; protein drugs.

Mesh:

Substances:

Year:  2018        PMID: 29848260     DOI: 10.2174/0929866525666180530122835

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  7 in total

1.  A Urinary Drug-Disposing Approach as an Alternative to Intravesical Chemotherapy for Treating Nonmuscle Invasive Bladder Cancer.

Authors:  Vanessa Bellat; Adam O Michel; Charlene Thomas; Tracy Stokol; Benjamin B Choi; Benedict Law
Journal:  Cancer Res       Date:  2022-04-01       Impact factor: 12.701

Review 2.  Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy.

Authors:  Ziyin Huang; Cassandra E Callmann; Shuya Wang; Matthew K Vasher; Michael Evangelopoulos; Sarah Hurst Petrosko; Chad A Mirkin
Journal:  ACS Cent Sci       Date:  2022-05-20       Impact factor: 18.728

3.  Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology.

Authors:  Safieh Aghaabdollahian; Reza Ahangari Cohan; Dariush Norouzian; Fatemeh Davami; Mohammad Reza Asadi Karam; Fatemeh Torkashvand; Golnaz Vaseghi; Reza Moazzami; Sakineh Latif Dizaji
Journal:  Sci Rep       Date:  2019-02-27       Impact factor: 4.379

Review 4.  Potentials of Neuropeptides as Therapeutic Agents for Neurological Diseases.

Authors:  Xin Yi Yeo; Grace Cunliffe; Roger C Ho; Su Seong Lee; Sangyong Jung
Journal:  Biomedicines       Date:  2022-02-01

5.  Generation of KS-487 as a novel LRP1-binding cyclic peptide with higher affinity, higher stability and BBB permeability.

Authors:  Kotaro Sakamoto
Journal:  Biochem Biophys Rep       Date:  2022-10-08

6.  Design and Characterizations of Inhalable Poly(lactic-co-glycolic acid) Microspheres Prepared by the Fine Droplet Drying Process for a Sustained Effect of Salmon Calcitonin.

Authors:  Hideyuki Sato; Aiko Tabata; Tatsuru Moritani; Tadahiko Morinaga; Takahiro Mizumoto; Yoshiki Seto; Satomi Onoue
Journal:  Molecules       Date:  2020-03-13       Impact factor: 4.411

7.  Preclinical dosimetry models and the prediction of clinical doses of novel positron emission tomography radiotracers.

Authors:  Adam A Garrow; Jack P M Andrews; Zaniah N Gonzalez; Carlos A Corral; Christophe Portal; Timaeus E F Morgan; Tashfeen Walton; Ian Wilson; David E Newby; Christophe Lucatelli; Adriana A S Tavares
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.